This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Information on how to access prescribing information and adverse event reporting can be found at the bottom of the page.

Learn about the recommended CRESEMBA® dosing

Formulations and Strength1

Recommended dose1​​​​​​​

Dose adjustments1

No dose adjustment is necessary for:

  • Patients with renal impairment (including patients with end-stage renal disease) ​​​​​​​
  • Patients with mild or moderate hepatic impairment (Child-Pugh Classes A and B). CRESEMBA has not been studied in patients with severe hepatic impairment (Child-Pugh Class C). Use in these patients is not recommended unless the potential benefit is considered to outweigh the risks. These patients should be carefully monitored for potential drug toxicity.
  • Elderly patients; however the clinical experience in elderly patients is limited.

References:
  1. CRESEMBA GB Summary of Product Characteristics.
PP-CRB-GBR-1214. August 2021

Cresemba Dosing Guide

Download the Cresemba dosing guide.

Download here

** This is an optional area where footnotes can live.

Training

 Find out more

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020

Yes

No